Show
Sort by
-
Residual cardiovascular risk is tracked by apolipoprotein B in coronary patients with elevated serum triglyceride levels : the ESC EORP EUROASPIRE IV survey
-
2025 focused update of the 2019 ESC/EAS guidelines for the management of dyslipidaemias : developed by the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)
-
2021 ESC guidelines on cardiovascular disease prevention in clinical practice
-
Medical treatment in coronary patients : is there still a gender gap? Results from European Society of Cardiology EUROASPIRE V Registry
-
2021 ESC Guidelines on cardiovascular disease prevention in clinical practice developed by the Task Force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies with the special contribution of the European Association of Preventive Cardiology (EAPC)
-
Percentage low-density lipoprotein-cholesterol response to a given statin dose is not fixed across the pre-treatment range : real world evidence from clinical practice : data from the ESC-EORP EUROASPIRE V study
-
2019 ESC/EAS Guidelines for the management of dyslipidaemias : lipid modification to reduce cardiovascular risk The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)
-
Incidence of cardiovascular events in patients with stabilized coronary heart disease : the EUROASPIRE IV follow-up study
-
Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries : results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry
-
The gender gap in risk factor control: effects of age and education on the control of cardiovascular risk factors in male and female coronary patients: the EUROASPIRE IV study by the European Society of Cardiology